Atropos Health announces renewed agreement with Janssen to accelerate real-world evidence generation

Atropos Health and Janssen’s renewed collaboration will support rapid real-world evidence generation for clinical development.

Atropos Health, a pioneer in evidence-based healthcare known for its Green Button Clinical Informatics Consult Service, has announced a renewed agreement with Janssen Research & Development LLC, a Johnson & Johnson company, to enhance clinical development through synergistic collaboration in real-world data (RWD) analysis and real-world evidence (RWE) generation.  

Atropos issued a press release publicizing the fresh plans to build upon an existing alliance between Atropos Health and Janssen. Under the renewed agreement, Atropos and Janssen data scientists will both utilize Atropos’s software platform to interrogate Janssen’s extensive in-house RWD sets. The RWE derived, spanning a broad portfolio of therapeutic areas, will be used to inform clinical development strategies, including optimizing trial design, understanding patient natural histories and assessing outcomes in real-world patient populations.  

“Atropos Health’s core mission is to close the evidence gap for patients worldwide,” said Brigham Hyde, CEO and Co-Founder of Atropos Health. “We are thrilled to collaborate with Janssen R&D’s world-class data scientists to support efforts to generate insights that could help optimize and accelerate clinical trials.” 

Atropos Health has previously forged similar collaborations with OMNY Health and Mayo Clinic Platform.  

Life science company partners can employ the AI-powered Atropos Evidence Platform, featuring the ground-breaking Green Button Clinical Informatics Consult Service, in combination with cloud-based data integration to maximize their existing RWD assets. Analysis of their in-house data platforms behind firewalls, including iterative hypothesis testing, protocol feasibility, cohort analysis, treatment pathways, patient journeys, unmet need, etc., can generate private libraries of evidence within 48 hours.  

Atropos also offer their own vast resource of RWD, the Atropos Evidence Network, boosting information access and therefore study capabilities. A significant feature of the network is their Real-World Fitness Score (RWFS™) rating of all the evidence, which indicates the fitness of the underlying data for the study. This feature is designed to facilitate users identifying fit-for-purpose data.